NASDAQ:ALIM Alimera Sciences (ALIM) Stock Price, News & Analysis $5.57 -0.02 (-0.36%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.56▼$5.6050-Day Range$2.89▼$5.6052-Week Range$2.61▼$5.65Volume1.34 million shsAverage Volume199,908 shsMarket Capitalization$291.81 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Alimera Sciences alerts: Email Address Alimera Sciences MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside43.6% Upside$8.00 Price TargetShort InterestHealthy1.18% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.76Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.13) to $0.21 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.54 out of 5 starsMedical Sector515th out of 936 stocksPharmaceutical Preparations Industry234th out of 436 stocks 3.0 Analyst's Opinion Consensus RatingAlimera Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAlimera Sciences has only been the subject of 3 research reports in the past 90 days.Read more about Alimera Sciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.18% of the outstanding shares of Alimera Sciences have been sold short.Short Interest Ratio / Days to CoverAlimera Sciences has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alimera Sciences has recently increased by 169.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlimera Sciences does not currently pay a dividend.Dividend GrowthAlimera Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALIM. Previous Next 2.6 News and Social Media Coverage News SentimentAlimera Sciences has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Alimera Sciences this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ALIM on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Alimera Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alimera Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders31.40% of the stock of Alimera Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.83% of the stock of Alimera Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alimera Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alimera Sciences are expected to grow in the coming year, from ($0.13) to $0.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alimera Sciences is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alimera Sciences is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlimera Sciences has a P/B Ratio of 6.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alimera Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Alimera Sciences Stock (NASDAQ:ALIM)Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.Read More ALIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALIM Stock News HeadlinesJuly 26 at 3:52 PM | prnewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIMJuly 26 at 5:40 AM | americanbankingnews.comAlimera Sciences, Inc. (NASDAQ:ALIM) Short Interest UpdateJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 25 at 3:19 PM | finance.yahoo.comInvesting in Alimera Sciences (NASDAQ:ALIM) a year ago would have delivered you a 68% gainJuly 20, 2024 | americanbankingnews.comAlimera Sciences (NASDAQ:ALIM) Stock Price Passes Above 200-Day Moving Average of $3.86July 20, 2024 | americanbankingnews.comStockNews.com Begins Coverage on Alimera Sciences (NASDAQ:ALIM)July 3, 2024 | globenewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. – ALIMJuly 2, 2024 | prnewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIMJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 24, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Alimera Sciences, Inc. has obtained a Fair Price for its Public ShareholdersJune 24, 2024 | investorplace.comWhy Is Alimera Sciences (ALIM) Stock Up 77% Today?June 24, 2024 | globenewswire.comALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI PharmaceuticalsJune 24, 2024 | businesswire.comALIM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alimera Sciences, Inc. Is Fair to ShareholdersJune 4, 2024 | globenewswire.comAlimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 16, 2024 | markets.businessinsider.comRobust Growth and Promising Trials: Buy Rating for Alimera SciencesMay 15, 2024 | finance.yahoo.comAlimera Sciences Inc (ALIM) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues and ...May 14, 2024 | globenewswire.comAlimera Sciences Reports First Quarter 2024 ResultsMay 7, 2024 | finance.yahoo.comAlimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress ConferencesSee More Headlines Receive ALIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/27/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALIM CUSIPN/A CIK1267602 Webwww.alimerasciences.com Phone(678) 990-5740Fax678-990-5744Employees154Year Founded2003Price Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+43.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,130,000.00 Net Margins-23.74% Pretax Margin-23.68% Return on Equity-53.49% Return on Assets-9.32% Debt Debt-to-Equity Ratio1.71 Current Ratio2.62 Quick Ratio2.51 Sales & Book Value Annual Sales$80.75 million Price / Sales3.61 Cash FlowN/A Price / Cash FlowN/A Book Value$0.88 per share Price / Book6.33Miscellaneous Outstanding Shares52,390,000Free Float35,939,000Market Cap$291.81 million OptionableOptionable Beta1.28 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Richard S. Eiswirth Jr. (Age 56)CEO & Director Comp: $949.27kMr. Jason Werner (Age 46)Chief Operating Officer Comp: $225.66kDr. Philip Ashman Ph.D. (Age 59)President of International Operations Comp: $516.98kMr. David R. Holland (Age 60)Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets Comp: $413.5kMr. Elliot Maltz CPA (Age 39)CFO & Treasurer Christopher S. VisickVP, General Counsel & SecretaryDr. David Dyer M.D.Chief Retina SpecialistMr. Todd Michael Wood (Age 55)President of U.S. Operations More ExecutivesKey CompetitorsEnliven TherapeuticsNASDAQ:ELVNCalliditas Therapeutics AB (publ)NASDAQ:CALTTyra BiosciencesNASDAQ:TYRADisc MedicineNASDAQ:IRONInnovivaNASDAQ:INVAView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 61,907 shares on 7/26/2024Ownership: 0.118%Deltec Asset Management LLCBought 124,169 shares on 7/16/2024Ownership: 0.237%Ancora Advisors LLCBought 234,620 shares on 5/16/2024Ownership: 0.448%Hillsdale Investment Management Inc.Bought 43,400 shares on 5/11/2024Ownership: 0.083%Vanguard Group Inc.Bought 396,506 shares on 5/10/2024Ownership: 1.996%View All Insider TransactionsView All Institutional Transactions ALIM Stock Analysis - Frequently Asked Questions How have ALIM shares performed this year? Alimera Sciences' stock was trading at $4.32 at the beginning of 2024. Since then, ALIM shares have increased by 28.9% and is now trading at $5.57. View the best growth stocks for 2024 here. How were Alimera Sciences' earnings last quarter? Alimera Sciences, Inc. (NASDAQ:ALIM) issued its quarterly earnings data on Tuesday, May, 14th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.08. The biopharmaceutical company earned $23.01 million during the quarter, compared to analysts' expectations of $23.72 million. Alimera Sciences had a negative net margin of 23.74% and a negative trailing twelve-month return on equity of 53.49%. When did Alimera Sciences' stock split? Alimera Sciences shares reverse split on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is Rick Eiswirth's approval rating as Alimera Sciences' CEO? 2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Alimera Sciences' major shareholders? Alimera Sciences' top institutional investors include Deltec Asset Management LLC (0.24%), Bank of New York Mellon Corp (0.12%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Caligan Partners Lp, Adam Morgan, Alto Investors Lp Palo, Stanley Morgan, John Philip Jones, Richard S Eiswirth Jr and James R Largent. View institutional ownership trends. How do I buy shares of Alimera Sciences? Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Alimera Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN) and AngloGold Ashanti (AU). This page (NASDAQ:ALIM) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alimera Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alimera Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.